Seattle Genetics Inc. (Seagen) started its second-ever phase III study, pitting a CD33-targeted antibody-drug conjugate paired with widely used hypomethylating agents (HMA) vs. HMAs alone in older patients with newly diagnosed acute myeloid leukemia (AML).